SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Canopy Growth Corporation (OTCMKTS:TWMJF) reported fiscal 2Q2017 financial report last week, with some positive growth recorded. The growth for company comprises continual revenue growth compared to the last quarter and the same quarter last year. This comes to revenue of around $8.5 million. This closed in $5.4 million as net income for 2Q2017 as compared to $3.9 million in the comparable quarter, a year earlier. Up around 80% in the last one week, the market may be waiting for a pullback to take a long position in the stock.

Marijuana stock prices jumped leading into the election as pot legalization advocates flooded the markets with dicey trades. Not of concern though, the buying prospects have not vanished away. As evident in the performance of certain cannabis firms, many of them are down in the last five days despite encouraging news and fundamental industry development to come.

Much of the hype seen into share prices moving into the election has reduced due to the profit taking after the election. Since a large number of the swing-traders have closed their positions, this offers nice entry prospects for those with longer-term stance to take a position.

Second quarter performance

Canopy Growth recently posted its financial numbers for 2Q2017 concluded September 30, 2016. All figures mentioned in this here forth are in Canadian dollars. The revenue jumped 22% to $8.5 million over 1Q2017, while it represented an increase of 245% over the same quarter, a year earlier. Bruce Linton, the CEO and Chairman, stated that improvement in registered subjects led in stronger revenues in 2Q2017. The company considers that quality, steadiness and diversity of supply are reasons in driving market share in the mounting legalized cannabis market.

Linton mentioned that he has noted Tweed release robust genetics and improved applications into its production mechanisms, impacting quality in a positive way and retiring earlier strains.

SHARE
Previous articleMGT Capital Investments Inc. (OTCMKTS:MGTI) Engages John McAfee as CEO
Next articleWhat Is The Buzz Surrounding Aphria Inc. (OTCMKTS:APHQF)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.